- Home
- / Exelixis
Exelixis
Stock Price
$28.7
2024-10-29
Market Capitalization
$8.2 B
2024-10-29
Revenue
$2.3 B
FY, 2025
Exelixis Summary
Company Summary
- Overview
- Exelixis is an oncology company that develops cancer treatments. It provides CABOMETYX, tablets for advanced renal cell carcinoma; COMETRIQ, capsules for progressive, metastatic medullary thyroid cancer; COTELLIC, an inhibitor of MEK; and MINNEBRO, an oral, non-steroidal, selective blocker of the mineralocorticoid receptor.
- Type
- Public
- Status
- Active
- Founded
- 1994
- HQ
- Alameda, CA, US | view all locations
- Website
- https://www.exelixis.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Vicki L. Goodman, Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
Christopher J. Senner, Executive Vice President and Chief Financial Officer
Dana T. Aftab, Executive Vice President, Business Operations
LocationsView all
1 location detected
Alameda, CA HQ
United States
1851 Harbor Bay Pkwy
Exelixis Financials
Summary Financials
- Revenue (Q1, 2026)
- $610.8M
- Gross profit (Q1, 2026)
- $590.9M
- Net income (Q1, 2026)
- $210.5M
- Cash (Q1, 2026)
- $226.2M
- EBIT (Q1, 2026)
- $251.3M
- Enterprise value
- $8.1B